Hainan Haiyao Co., Ltd. (SHE:000566)
China · Delayed Price · Currency is CNY 5.41
-0.42 (-7.20%)
Jul 29, 2026, 3:04 PM CST
Hainan Haiyao Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 792.76 | 831.18 | 990.7 | 1,479 | 1,779 | 2,059 |
Revenue Growth | -4.98% | -16.10% | -33.00% | -16.89% | -13.60% | -6.42% |
Gross Profit Gross Profit Growth | 177.92 | 198.04 | 321.75 | 570.98 | 767.71 | 825.69 |
Operating Income Operating Income Growth | -266.84 | -247.65 | -619.12 | 0.66 | -127.82 | -697.3 |
Net Income Net Income Growth | -438.08 | -429.99 | -1,525 | -106.49 | 10.51 | -1,555 |
Earnings Per Share EPS Growth | -0.34 | -0.33 | -1.18 | -0.08 | 0.01 | -1.20 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Traditional Chinese Medicinal Materials Wareshouding and Trading Traditional Chinese Medicinal Materials Wareshouding and Trading Growth | 57.41 |
Sale and Manufacturing of Active Pharmaceutical Ingredients Sale and Manufacturing of Active Pharmaceutical Ingredients Growth | 166.79 |
Others Others Growth | 214.76 |
Manufacturing and Sale of Medicine Preparation Manufacturing and Sale of Medicine Preparation Growth | 443.52 |
Intersegment Elimination Intersegment Elimination Growth | -62.96 |
Total Total Growth | 819.52 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 635.78 | 525.08 | 521.68 | 932.99 | 974.53 | 1,597 |
Total Debt Total Debt Growth | 5,029 | 4,726 | 4,502 | 4,176 | 4,051 | 4,403 |
Net Cash (Debt) Net Cash Growth | -4,393 | -4,201 | -3,981 | -3,243 | -3,077 | -2,806 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -3.39 | -3.24 | -3.07 | -2.50 | -2.37 | -2.16 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 99.2 | 79.8 | -17.55 | 103.55 | 142.17 | 108.22 |
Capital Expenditures CapEx Growth | -145.06 | -143.25 | -175.58 | -210.69 | -263.78 | -415.08 |
Free Cash Flow Free Cash Flow Growth | -45.86 | -63.44 | -193.13 | -107.14 | -121.61 | -306.86 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 22.44% | 23.83% | 32.48% | 38.62% | 43.15% | 40.10% |
Operating Margin | -33.66% | -29.79% | -62.49% | 0.04% | -7.18% | -33.87% |
Pretax Margin | -51.80% | -49.05% | -157.58% | -8.02% | -3.31% | -75.57% |
Profit Margin | -55.26% | -51.73% | -153.95% | -7.20% | 0.59% | -75.54% |
FCF Margin | -5.78% | -7.63% | -19.50% | -7.25% | -6.84% | -14.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | - | - | 527.26 | - |
Forward PE | - | 28.80 | 28.80 | 28.80 | 28.80 | 28.80 |
PS Ratio | 9.54 | 11.16 | 6.27 | 3.97 | 3.11 | 3.31 |